{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:57:14Z","timestamp":1787615834319,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T00:00:00Z","timestamp":1714262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T00:00:00Z","timestamp":1714262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1245\/s10434-024-15328-3","type":"journal-article","created":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T13:01:28Z","timestamp":1714309288000},"page":"4551-4557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Presacral Neuroendocrine Neoplasms: A Multi-site Review of Surgical Outcomes"],"prefix":"10.1245","volume":"31","author":[{"given":"Tommaso","family":"Violante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rondell P.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Navin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Merchea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Dozois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,28]]},"reference":[{"issue":"1","key":"15328_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1479-666X(07)80109-0","volume":"5","author":"J Ghosh","year":"2007","unstructured":"Ghosh J, Eglinton T, Frizelle FA, Watson AJ. Presacral tumours in adults. Surgeon. 2007;5(1):31\u20138.","journal-title":"Surgeon"},{"issue":"9","key":"15328_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/BF02553440","volume":"28","author":"SW Jao","year":"1985","unstructured":"Jao SW, Beart RW Jr, Spencer RJ, Reiman HM, Ilstrup DM. Retrorectal tumors. Mayo Clinic experience, 1960\u20131979. Dis Colon Rectum. 1985;28(9):644\u201352.","journal-title":"Dis Colon Rectum."},{"issue":"10","key":"15328_CR3","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1007\/s10350-005-0122-9","volume":"48","author":"KG Hobson","year":"2005","unstructured":"Hobson KG, Ghaemmaghami V, Roe JP, Goodnight JE, Khatri VP. Tumors of the retrorectal space. Dis Colon Rectum. 2005;48(10):1964\u201374.","journal-title":"Dis Colon Rectum."},{"issue":"12","key":"15328_CR4","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s11605-013-2350-y","volume":"17","author":"CA Messick","year":"2013","unstructured":"Messick CA, Hull T, Rosselli G, Kiran RP. Lesions originating within the retrorectal space: a diverse group requiring individualized evaluation and surgery. J Gastrointest Surg. 2013;17(12):2143\u201352.","journal-title":"J Gastrointest Surg."},{"key":"15328_CR5","first-page":"449","volume":"115","author":"RJ Spencer","year":"1962","unstructured":"Spencer RJ, Jackman RJ. Surgical management of precoccygeal cysts. Surg Gynecol Obstet. 1962;115:449\u201352.","journal-title":"Surg Gynecol Obstet."},{"key":"15328_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/978-3-030-66049-9_21","volume-title":"The ASCRS Textbook of Colon and Rectal Surgery","author":"SR Kelley","year":"2022","unstructured":"Kelley SR, Dozois EJ. Presacral Tumors. In: SR Steele, TL Hull, N Hyman, JA Maykel, TE Read, CB Whitlow, editors. The ASCRS Textbook of Colon and Rectal Surgery. Cham: Springer International Publishing; 2022. p. 375\u201396."},{"issue":"4","key":"15328_CR7","doi-asserted-by":"publisher","first-page":"e13264","DOI":"10.1111\/jne.13264","volume":"35","author":"E Thiis-Evensen","year":"2023","unstructured":"Thiis-Evensen E, Boyar Cetinkaya R. Incidence and prevalence of neuroendocrine neoplasms in Norway 1993\u20132021. J Neuroendocrinol. 2023;35(4):e13264.","journal-title":"J Neuroendocrinol."},{"issue":"4","key":"15328_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","volume":"23","author":"S Das","year":"2021","unstructured":"Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: Are there global differences? Curr Oncol Rep. 2021;23(4):43.","journal-title":"Curr Oncol Rep."},{"issue":"8","key":"15328_CR9","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.ejca.2012.12.022","volume":"49","author":"CM Korse","year":"2013","unstructured":"Korse CM, Taal BG, van Velthuysen ML, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of 2 decades of cancer registry. Eur J Cancer. 2013;49(8):1975\u201383.","journal-title":"Eur J Cancer"},{"issue":"4","key":"15328_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589\u201397.","journal-title":"Cancer"},{"key":"15328_CR11","doi-asserted-by":"publisher","first-page":"100510","DOI":"10.1016\/j.lanepe.2022.100510","volume":"23","author":"BE White","year":"2022","unstructured":"White BE, Rous B, Chandrakumaran K, Wong K, Bouvier C, Van Hemelrijck M, et al. Incidence and survival of neuroendocrine neoplasia in England 1995\u20132018: a retrospective, population-based study. Lancet Reg Health Eur. 2022;23:100510.","journal-title":"Lancet Reg Health Eur."},{"issue":"Suppl 1","key":"15328_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000080731","volume":"80","author":"BG Taal","year":"2004","unstructured":"Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80(Suppl 1):3\u20137.","journal-title":"Neuroendocrinology"},{"key":"15328_CR13","doi-asserted-by":"publisher","first-page":"709256","DOI":"10.3389\/fendo.2021.709256","volume":"12","author":"S Matrood","year":"2021","unstructured":"Matrood S, Apostolidis L, Schrader J, Krug S, Lahner H, Ramaswamy A, et al. Multicenter analysis of presacral neuroendocrine neoplasms-clinicopathological characterization and treatment outcomes of a rare disease. Front Endocrinol (Lausanne). 2021;12:709256.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"15328_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1385\/EP:14:4:293","volume":"14","author":"RV Lloyd","year":"2003","unstructured":"Lloyd RV. Practical markers used in the diagnosis of neuroendocrine tumors. Endocr Pathol. 2003;14(4):293\u2013301.","journal-title":"Endocr Pathol."},{"issue":"4","key":"15328_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"15328_CR16","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s10350-005-0048-2","volume":"48","author":"SC Glasgow","year":"2005","unstructured":"Glasgow SC, Birnbaum EH, Lowney JK, Fleshman JW, Kodner IJ, Mutch DG, et al. Retrorectal tumors: a diagnostic and therapeutic challenge. Dis Colon Rectum. 2005;48(8):1581\u20137.","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"15328_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/MPA.0000000000000954","volume":"47","author":"G Yang","year":"2018","unstructured":"Yang G, Dhall D, Yu R, Tuli R, Amersi FF, Friedman ML, et al. The Clinicopathological aspects of primary presacral neuroendocrine neoplasms: one center experience. Pancreas. 2018;47(1):122\u20139.","journal-title":"Pancreas"},{"issue":"4","key":"15328_CR18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cncr.11105","volume":"97","author":"IM Modlin","year":"2003","unstructured":"Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934\u201359.","journal-title":"Cancer"},{"issue":"5","key":"15328_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.4103\/0028-3886.103219","volume":"60","author":"W Zhong","year":"2012","unstructured":"Zhong W, You C, Chen H, Huang S. Primary presacral carcinoid tumor with gluteal muscle metastasis. Neurol India. 2012;60(5):544\u20135.","journal-title":"Neurol India"},{"issue":"8","key":"15328_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00256-009-0693-y","volume":"38","author":"F Dujardin","year":"2009","unstructured":"Dujardin F, Beaussart P, de Muret A, Rosset P, Waynberger E, Mulleman D, de Pinieux G. Primary neuroendocrine tumor of the sacrum: case report and review of the literature. Skeletal Radiol. 2009;38(8):819\u201323.","journal-title":"Skeletal Radiol"},{"issue":"3","key":"15328_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1227\/00006123-198803000-00025","volume":"22","author":"MS Fiandaca","year":"1988","unstructured":"Fiandaca MS, Ross WK, Pearl GS, Bakay RA. Carcinoid tumor in a presacral teratoma associated with an anterior sacral meningocele: case report and review of the literature. Neurosurgery. 1988;22(3):581\u20138.","journal-title":"Neurosurgery"},{"issue":"4","key":"15328_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10151-018-1781-6","volume":"22","author":"TG Mullaney","year":"2018","unstructured":"Mullaney TG, Lightner AL, Johnston M, Kelley SR, Larson DW, Dozois EJ. A systematic review of minimally invasive surgery for retrorectal tumors. Tech Coloproctol. 2018;22(4):255\u201363.","journal-title":"Tech Coloproctol"},{"issue":"4","key":"15328_CR23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.dld.2004.10.014","volume":"37","author":"TV Luong","year":"2005","unstructured":"Luong TV, Salvagni S, Bordi C. Presacral carcinoid tumour. Review of the literature and report of a clinically malignant case. Dig Liver Dis. 2005;37(4):278\u201381.","journal-title":"Dig Liver Dis."},{"issue":"3","key":"15328_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4103\/ijri.IJRI_148_19","volume":"29","author":"S Chatani","year":"2019","unstructured":"Chatani S, Onaya H, Kato S, Inaba Y. Adenocarcinoma and neuroendocrine tumor arising within presacral teratoma associated with Currarino syndrome: a case report. Indian J Radiol Imaging. 2019;29(3):327\u201331.","journal-title":"Indian J Radiol Imaging"},{"issue":"3","key":"15328_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/02688697.2017.1339226","volume":"33","author":"F Colombo","year":"2019","unstructured":"Colombo F, Janous P, Buxton N. Carcinoid transformation of presacral dermoid cyst in patient with currarino syndrome: a case report. Br J Neurosurg. 2019;33(3):285\u20136.","journal-title":"Br J Neurosurg."},{"issue":"4","key":"15328_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.17159\/2078-5151\/2019\/v57n4a3145","volume":"57","author":"E Coetzee","year":"2019","unstructured":"Coetzee E, Malaka S. Malignant neuroendocrine tumour in an adult female diagnosed with Currarino syndrome. S Afr J Surg. 2019;57(4):44.","journal-title":"S Afr J Surg."},{"issue":"11","key":"15328_CR27","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00384-010-0953-2","volume":"25","author":"R Pendlimari","year":"2010","unstructured":"Pendlimari R, Leonard D, Dozois EJ. Rare malignant neuroendocrine transformation of a presacral teratoma in patient with Currarino syndrome. Int J Colorectal Dis. 2010;25(11):1383\u20134.","journal-title":"Int J Colorectal Dis."},{"issue":"Suppl 1","key":"15328_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.gastrohep.2021.03.009","volume":"45","author":"A Correa Bonito","year":"2022","unstructured":"Correa Bonito A, Maqueda Gonz\u00e1lez R, Rodr\u00edguez S\u00e1nchez A, Bermejo Marcos E, Blanco Ter\u00e9s L, Garc\u00eda Septiem J, Mart\u00edn P\u00e9rez E. Presacral neuroendocrine tumour in a patient diagnosed with Currarino\u2019s syndrome. Gastroenterol Hepatol. 2022;45(Suppl 1):62\u20133.","journal-title":"Gastroenterol Hepatol."},{"issue":"5","key":"15328_CR29","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/ajmg.a.62145","volume":"185","author":"AT Scott","year":"2021","unstructured":"Scott AT, Tessmann JB, Braun T, Brown B, Breheny PJ, Darbro BW, et al. Presacral neuroendocrine tumors associated with the Currarino syndrome. Am J Med Genet A. 2021;185(5):1582\u20138.","journal-title":"Am J Med Genet A."},{"issue":"8","key":"15328_CR30","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1097\/MPA.0000000000001632","volume":"49","author":"AJ Liu","year":"2020","unstructured":"Liu AJ, Halfdanarson TR, Sonbol MB. Currarino syndrome: a rare condition with potential connection to neuroendocrine tumors. Pancreas. 2020;49(8):1104\u20138.","journal-title":"Pancreas"},{"issue":"3","key":"15328_CR31","doi-asserted-by":"publisher","first-page":"E185","DOI":"10.1097\/BRS.0b013e31827db1ba","volume":"38","author":"A Angelini","year":"2013","unstructured":"Angelini A, Ruggieri P. A new surgical technique (modified Osaka technique) of sacral resection by posterior-only approach: description and preliminary results. Spine (Phila Pa 1976). 2013;38(3):E185\u201392.","journal-title":"Spine (Phila Pa 1976)"},{"issue":"4","key":"15328_CR32","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/codi.16030","volume":"24","author":"SP Broccard","year":"2022","unstructured":"Broccard SP, Colibaseanu DT, Behm KT, Mishra N, Davis P, Maimone KL, et al. Risk of malignancy and outcomes of surgically resected presacral tailgut cysts: a current review of the Mayo Clinic experience. Colorectal Dis. 2022;24(4):422\u20137.","journal-title":"Colorectal Dis."},{"issue":"32","key":"15328_CR33","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1200\/JCO.23.01529","volume":"41","author":"J Del Rivero","year":"2023","unstructured":"Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, et al. Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline. J Clin Oncol. 2023;41(32):5049\u201367.","journal-title":"J Clin Oncol."},{"issue":"3","key":"15328_CR34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, Phan AT, Raderer M, Sedl\u00e1\u010dkov\u00e1 E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333.","journal-title":"N Engl J Med."},{"issue":"28","key":"15328_CR35","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656\u201363.","journal-title":"J Clin Oncol."},{"key":"15328_CR36","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.12659\/AJCR.921439","volume":"20","author":"MR Kim","year":"2019","unstructured":"Kim MR, Shim HK. Long-term follow-up of a patient with primary presacral neuroendocrine tumor: a case report with literature review. Am J Case Rep. 2019;20:1969\u201375.","journal-title":"Am J Case Rep."},{"issue":"4","key":"15328_CR37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3109\/03009734.2015.1054453","volume":"120","author":"UG Falkmer","year":"2015","unstructured":"Falkmer UG, Gustafsson T, Wenzel R, Wierup N, Sundler F, Kulkarni H, et al. Malignant presacral ghrelinoma with long-standing hyperghrelinaemia. Ups J Med Sci. 2015;120(4):299\u2013304.","journal-title":"Ups J Med Sci."},{"issue":"2","key":"15328_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med."},{"issue":"16","key":"15328_CR39","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0), Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617\u201324.","journal-title":"Clin Cancer Res."},{"key":"15328_CR40","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264043","author":"S Ballal","year":"2022","unstructured":"Ballal S, Yadav MP, Tripathi M, Sahoo RK, Bal C. Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant (225)Ac-DOTATATE targeted alpha therapy and capecitabine: a real-world scenario management based long-term outcome study. J Nucl Med. 2022. https:\/\/doi.org\/10.2967\/jnumed.122.264043.","journal-title":"J Nucl Med."},{"issue":"9","key":"15328_CR41","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","volume":"63","author":"ES Delpassand","year":"2022","unstructured":"Delpassand ES, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A, N\u00fa\u00f1ez R. Targeted \u03b1-emitter therapy with (212)Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-humans dose-escalation clinical trial. J Nucl Med. 2022;63(9):1326\u201333.","journal-title":"J Nucl Med."},{"issue":"10022","key":"15328_CR42","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968\u201377.","journal-title":"Lancet"},{"key":"15328_CR43","doi-asserted-by":"publisher","first-page":"S1292","DOI":"10.1016\/j.annonc.2023.10.047","volume":"34","author":"J Chan","year":"2023","unstructured":"Chan J, Geyer S, Ou FS, Knopp M, Behr S, Zemla T, et al. LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET). Ann Oncol. 2023;34:S1292.","journal-title":"Ann Oncol."},{"issue":"2","key":"15328_CR44","doi-asserted-by":"publisher","first-page":"e220290","DOI":"10.1001\/jamanetworkopen.2022.0290","volume":"5","author":"S Pusceddu","year":"2022","unstructured":"Pusceddu S, Prinzi N, Tafuto S, Ibrahim T, Filice A, Brizzi MP, et al. Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors. JAMA Netw Open. 2022;5(2):e220290.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"15328_CR45","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1245\/s10434-023-13372-z","volume":"30","author":"H Gudmundsdottir","year":"2023","unstructured":"Gudmundsdottir H, Habermann EB, Vierkant RA, Starlinger P, Thiels CA, Warner SG, et al. Survival and symptomatic relief after cytoreductive hepatectomy for neuroendocrine tumor liver metastases: long-term follow-up evaluation of more than 500 patients. Ann Surg Oncol. 2023;30(8):4840\u201351.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15328-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15328-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15328-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T16:15:12Z","timestamp":1718036112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15328-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,28]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["15328"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15328-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,28]]},"assertion":[{"value":"1 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Thorvardur Halfdanarson has received research support from Thermo Fisher Scientific, Advanced Accelerator Applications (a Novartis company), Camurus, Crinetics, and ITM Isotopen Technologien Muenchen. He has also undertaken consultancy\/advisory board\/steering committee work for Ipsen, TerSera, Advanced Accelerator Applications (a Novartis company), Terumo, ITM Isotopen Technologien Muenchen, Crinetics, Perspective Therapeutics, and Camurus. Tommaso Violante, Brenda Murphy, Davide Ferrari, Rondell P. Graham, Patrick Navin, Amit Merchea, David W. Larson, Eric J. Dozois, and William R. Perry have no conflicts of interest to disclose in relation to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}